Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2016 08:05 ET | Source: Advaxis

Advaxis to Host Investor & Analyst Day on June 28, 2016

PRINCETON, N.J., May 17, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that they will host their...
May 05, 2016 09:24 ET | Source: Advaxis

UPDATE – Advaxis to Present at Jefferies 2016 Healthcare Conference

PRINCETON, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O’Connor,...
May 05, 2016 08:35 ET | Source: Advaxis

Advaxis to Present at Jeffries 2016 Healthcare Conference

PRINCETON, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that Daniel J. O’Connor,...
April 28, 2016 07:05 ET | Source: Advaxis

FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma

PRINCETON, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that the Food and Drug...
April 25, 2016 08:05 ET | Source: Advaxis

Phase II Cervical Cancer Study with Advaxis’ Axalimogene Filolisbac Selected for Poster Discussion Session at the 2016 ASCO Annual Meeting

Poster Discussion Sessions highlight the most clinically applicable and novel posters PRINCETON, N.J., April 25, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical...
April 19, 2016 09:05 ET | Source: Advaxis

AACR Research Reception Featured Late-Breaking Poster on Lm Technology™ Platform

Reception included update on the Company’s MINE program(My Immunotherapy Neo-Epitopes) /ADXS-NEO immunotherapy STING Pathway and Advaxis’ Lm Technology™ highlighted Slides and audio are available...
April 18, 2016 07:05 ET | Source: Advaxis

Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company’s Lm Technology™ Platform

PRINCETON, N.J., April 18, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced immunological and...
April 13, 2016 08:00 ET | Source: Advaxis

Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform

First biotechnology company to ever receive Vision of Hope Award PRINCETON, N.J., April 13, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing...
April 05, 2016 08:00 ET | Source: Advaxis

Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts

Study Evaluating ADXS-PSA Launches Third Dose-Escalation Cohort Part B Combination with 51 Patients to Begin Mid-Year PRINCETON, N.J., April 05, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc....
April 04, 2016 09:05 ET | Source: Advaxis

Advaxis to Present at the 3rd Annual Jefferies Immuno-Oncology Summit

PRINCETON, N.J., April 04, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, will present at the 3rd Annual Jefferies...